# HUTCHMED (HCM) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/HCM
## Company Profile
- Ticker: HCM
- Exchange: NASDAQ
- Sector: Biopharma
- Location: China and listed in the U
- Tags: Oncology, Immunology
## Stock Data
- Close: 11.55 USD
- Market cap: 1980868193.28 USD
- Last updated: 2026-08-05
## Business Overview
### China-Originated Oncology Company
HUTCHMED is an oncology-focused biopharmaceutical company with commercial products in China and partnered global products. Its strategy combines China commercialization, global partnerships, and internal R&D aimed at differentiated small molecules and newer antibody-targeted modalities.
### Commercial Oncology Portfolio
The company's commercial base includes ELUNATE, SULANDA, FRUZAQLA, ORPATHYS, and other oncology products. First-half 2026 growth was led by a rebound in China product sales and geographic expansion of FRUZAQLA outside China, which had approvals or launches in 41 countries.
### Late-Stage Regulatory Pipeline
HUTCHMED has multiple late-stage programs across oncology and immunology. Recent progress includes China approval of ELUNATE with sintilimab for second-line kidney cancer, China NDA acceptances for sovleplenib in wAIHA and ITP, ORPATHYS approval in third-line MET-amplified gastric cancer, and positive data for fanregratinib in FGFR2 fusion or rearrangement intrahepatic cholangiocarcinoma.
### ATTC Innovation Strategy
The company is investing in antibody-targeted therapy conjugates, or ATTCs, that use antibody targeting to deliver potent small-molecule payloads to tumor cells. HMPL-A251, HMPL-A580, and HMPL-A830 represent a newer platform layer intended to create first-in-class or best-in-class candidates and support multinational partnering opportunities.
## Why The Stock Is Moving

As of Aug 5, 2026, HCM was little changed and closed at $11.55. No new same-company headline was identified in the current news window.

## Future Catalysts

- Topline results from SAFFRON and SANOVO Phase 3 savolitinib studies in the second half of 2026.
- NMPA review of sovleplenib in wAIHA and ITP.
- Global clinical trial initiation for HMPL-A830 in the second half of 2026.

## Recent News
- 2026-07-30 11:00 EST — [HUTCHMED Reports 2026 Interim Results](https://biopharmsignal.com/news/HCM/hutchmed-reports-2026-interim-results-1642187b) — Source: HUTCHMED
- 2026-07-02 08:30 EST — [HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification](https://biopharmsignal.com/news/HCM/hutchmed-announces-nmpa-approval-for-orpathys-for-the-treatment-of-gastric-cance-e8d2b97e) — Source: HUTCHMED
- 2026-06-30 08:30 EST — [HUTCHMED to Announce 2026 Half-Year Financial Results](https://biopharmsignal.com/news/HCM/hutchmed-to-announce-2026-half-year-financial-results-cae79711) — Source: HUTCHMED
- 2026-06-25 00:00 EST — [HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026](https://biopharmsignal.com/news/HCM/hutchmed-highlights-pivotal-phase-ii-data-for-fanregratinib-in-intrahepatic-chol-bda8536d) — Source: HUTCHMED
- 2026-06-12 00:00 EST — [HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress](https://biopharmsignal.com/news/HCM/hutchmed-highlights-sovleplenib-eslim-02-phase-iii-data-in-warm-antibody-autoimm-110d8144) — Source: HUTCHMED